Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2017-03-31 Regulatory Filings
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings
2017-03-31 English
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events or material definitive agreements. The text describes the entry into material definitive agreements with BARDA, including contract details and modifications. It references that the full contract will be filed as an exhibit to the upcoming Quarterly Report on Form 10-Q, indicating this document is an announcement of contract agreements rather than a full financial or operational report. The document length is 4613 characters, which is relatively short and consistent with an 8-K filing. There is no detailed financial data or comprehensive report content, so it does not qualify as an Annual Report (10-K), Quarterly Report (IR), or other detailed financial filings. The content fits best under Capital/Financing Update (CAP) as it relates to significant contract agreements impacting company financing and operations. Therefore, the classification is CAP with high confidence.
2017-03-17 English
FORM 4
Director's Dealing
2017-03-16 English
FORM 4
Director's Dealing
2017-03-11 English
FORM 4
Director's Dealing
2017-03-11 English
FORM 4
Director's Dealing
2017-03-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.